Read + Share
Albers J, Friese-Hamim M, Clark A, Schadt O, et al. The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with
Activity in Tumors Harboring MET Alterations. Mol Cancer Ther 2023;22:833-843.
PMID: 36999986
|
 |
|
Albers J, Friese-Hamim M, Clark A, Schadt O, et al. The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with
Activity in Tumors Harboring MET Alterations. Mol Cancer Ther 2023;22:833-843.
PMID: 36999986
|
|
|
|